Abstract
Introduction: Ovarian metastasis of colorectal cancer is known to have a poor prognosis. This study aimed to elucidate the characteristics of patients who underwent oophorectomy for ovarian metastasis from colorectal cancer. Methods: This retrospective study included 16 patients who underwent oophorectomy for colorectal cancer metastasis to the ovary from January 2004 to December 2017. Improvement in patient’s symptoms and pre- and postoperative changes in various nutritional and inflammatory indicators were assessed. Survival analysis and identification of prognostic factors were conducted with a median follow-up of 40.7 (5–109) months. Results: Of 16 patients, 12 had (75%) synchronous and 4 (25%) had metachronous metastasis. Fourteen patients were symptomatic but symptoms resolved postoperatively. Thirteen patients (81.3%) had ascites and 5 (31.3%) had pleural effusion on preoperative computed tomography that disappeared after surgery in all cases. The median value of prognostic nutritional factor was significantly increased postoperatively (36.0 [preoperatively] vs. 47.5, p < 0.0001). The median (interquartile range) values for lymphocyte-C-reactive protein ratio were 715.2 (110–2,607) preoperatively and 6,095.2 (1,612.3–14,431.8) postoperatively (p = 0.0214). The median survival of the entire cohort was 60.4 months. The 3-year survival rates for R0 + R1 and R2 cases were 83% and 24% (p = 0.018), respectively. Univariate analysis showed that R2 resection and low postoperative lymphocyte-C-reactive protein ratio were associated with poor prognosis. Conclusions: Oophorectomy for ovarian metastasis from colorectal cancers was safely performed. It improved the patients’ symptoms and nutritional status and may result in improved prognosis.
Journal Section:
Clinical Study
References
1.
Segelman
J
, Floter-Radestad
A
, Hellborg
H
, Sjövall
A
, Martling
A
. Epidemiology and prognosis of ovarian metastases in colorectal cancer
. Br J Surg
. 2010 Nov
97
11
1704
9
.2.
Birnkrant
A
, Sampson
J
, Sugarbaker
PH
. Ovarian metastasis from colorectal cancer
. Dis Colon Rectum
. 1986 Nov
29
11
767
71
.3.
Erroi
F
, Scarpa
M
, Angriman
I
, Cecchetto
A
, Pasetto
L
, Mollica
E
. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy
. J Surg Oncol
. 2007 Aug 1
96
2
113
7
.4.
De Waal
YRP
, Thomas
CMG
, Oei
ALM
, Sweep
F
, Massuger
L
. Secondary ovarian malignancies: frequency, origin, and characteristics
. Int J Gynecol Cancer
. 2009 Oct
19
7
1160
5
.5.
Lobo
J
, Machado
B
, Vieira
R
, Bartosch
C
. The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor
. Virchows Arch
. 2017 Jan
470
1
69
80
.6.
Chung
TS
, Chang
HJ
, Jung
KH
, Park
SY
, Lim
SB
, Choi
HS
. Role of surgery in the treatment of ovarian metastases from colorectal cancer
. J Surg Oncol
. 2009 Dec 1
100
7
570
4
.7.
Garrett
CR
, George
B
, Viswanathan
C
, Bhadkamkar
NA
, Wen
S
, Baladandayuthapani
V
. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary
. Clin Colorectal Cancer
. 2012 Sep
11
3
191
4
.8.
Onodera
T
, Goseki
N
, Kosaki
G
. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients
. Nihon Geka Gakkai Zasshi
. 1984 Sep
85
9
1001
5
.9.
Okugawa
Y
, Toiyama
Y
, Yamamoto
A
, Shigemori
T
, Ide
S
, Kitajima
T
. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer
. Ann Surg
. 2020 Aug
272
2
342
51
.10.
Park
JH
, Watt
DG
, Roxburgh
CSD
, Horgan
PG
, McMillan
DC
. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host
. Ann Surg
. 2016 Feb
263
2
326
36
.11.
Shah
B
, Tang
W
, Karn
S
. An up-to-date understanding of the “krukenberg tumor” mechanism
. Adv Reprod Sci
. 2016 May
4
2
31
6
.12.
Moore
RG
, Chung
M
, Granai
CO
, Gajewski
W
, Steinhoff
MM
. Incidence of metastasis to the ovaries from nongenital tract primary tumors
. Gynecol Oncol
. 2004 Apr
93
1
87
91
.13.
Graffner
HOL
, Alm
POA
, Oscarson
JEA
. Prophylactic Oophorectomy in colorectal carcinoma
. Am J Surg
. 1983 Aug
146
2
233
5
.14.
Asbun
HJ
, Hughes
KS
. Management of recurrent and metastatic colorectal carcinoma
. Surg Clin North Am
. 1993 Feb
73
1
145
66
.15.
Lee
KC
, Lin
H
, ChangChien
CC
, Fu
HC
, Tsai
CC
, Wu
CH
. Difficulty in diagnosis and different prognoses between colorectal cancer with ovarian metastasis and advanced ovarian cancer: an empirical study of different surgical adoptions
. Taiwan J Obstet Gynecol
. 2017 Feb
56
1
62
7
.16.
Dionigi
A
, Facco
C
, Tibiletti
MG
, Bernasconi
B
, Riva
C
, Capella
C
. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis
. Am J Clin Pathol
. 2000 Jul
114
1
111
22
.17.
18.
Yamaguchi
T
, Takahashi
H
, Kagawa
R
, Takeda
R
, Sakata
S
, Yamamoto
M
. The role of prophylactic bilateral oophorectomy at the time of initial diagnosis of a unilateral ovarian metastasis in cases with colorectal adenocarcinoma
. Hepatogastroenterology
. 2008 Mar–Apr
55
82–83
434
7
.19.
Tan
KL
, Tan
WS
, Lim
JF
, Eu
KW
. Krukenberg tumors of colorectal origin: a dismal outcome--experience of a tertiary center
. Int J Colorectal Dis
. 2010 Feb
25
2
233
8
.20.
Kim
DD
, Park
IJ
, Kim
HC
, Yu
CS
, Kim
JC
. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients
. Colorectal Dis
. 2009 Jan
11
1
32
8
.21.
McCormick
CC
, Giuntoli
RL
2nd, Gardner
GJ
, Schulick
RD
, Judson
K
, Ronnett
BM
. The role of cytoreductive surgery for colon cancer metastatic to the ovary
. Gynecol Oncol
. 2007 Jun
105
3
791
5
.22.
Wright
JD
, Powell
MA
, Mutch
DG
, Rader
JS
, Gibb
RK
, Huettner
PC
. Synchronous ovarian metastases at the time of laparotomy for colon cancer
. Gynecol Oncol
. 2004 Mar
92
3
851
5
.23.
Jiang
R
, Tang
J
, Cheng
X
, Zang
RY
. Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors
. Eur J Surg Oncol
. 2009
;35
(1
):92
–7
.24.
Li
X
, Huang
H
, Ran
L
, Fang
C
, Yu
Y
, Luo
M
. Impact of ovarian metastatectomy on survival outcome of colorectal cancer patients with ovarian metastasis: a retrospective study
. Cancer Manag Res
. 2020 Jun
12
4493
501
.25.
Ganesh
K
, Shah
RH
, Vakiani
E
, Nash
GM
, Skottowe
HP
, Yaeger
R
. Clinical and genetic determinants of ovarian metastases from colorectal cancer
. Cancer
. 2017 Apr 1
123
7
1134
43
.26.
Shin
EK
, Takizawa
BT
, Masters
L
, Shahabi
S
. The role of chemotherapy and prophylactic bilateral oophorectomy in a case of colorectal adenocarcinoma with ovarian metastases
. Yale J Biol Med
. 2001 Mar–Apr
74
2
101
5
.27.
Oikawa
Y
, Fujimoto
Y
, Akiyoshi
T
, Konishi
T
, Nagayama
S
, Fukunaga
Y
. Analysis of 20 patients who underwent oophorectomy for ovarian metastases from colorectal cancer
. Nihon Daityo-coumonbyou Zassi
. 2013
;66
(1
):1
–6
. (in Japanese) 28.
Ryan
RJ
. PseudoMeigs syndrome. Associated with metastatic cancer of ovary
. N Y State J Med
. 1972 Mar 15
72
6
727
30
.29.
Mithieux
F
, Coriat
R
, De La Fouchardière
C
, Méeus
P
, Rivoire
M
. Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer
. Gastroenterol Clin Biol
. 2008 Mar
32
3
261
4
.30.
Rhoads
JE
, Terrell
WE
. Ovarian fibroma with ascites and hydrothorax (Meigs’s syndrome): report of a case
. JAMA
. 1937 Nov
109
21
1684
7
.31.
Saito
H
, Koide
N
, Miyagawa
S
. Pseudo-Meigs syndrome caused by sigmoid colon cancer metastasis to the ovary
. Am J Surg
. 2012 Jan
203
1
e1
3
.32.
Yamamoto
Y
, Miyagawa
Y
, Ehara
T
, Koyama
M
, Nakamura
S
, Takeuchi
D
. Three cases of pseudo-meigs’ syndrome secondary to ovarian metastases from colorectal cancer
. Case Rep Surg
. 2017
;2017
:5235368
.33.
Tokunaga
R
, Sakamoto
Y
, Nakagawa
S
, Izumi
D
, Kosumi
K
, Taki
K
. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection
. Int J Clin Oncol
. 2017 Aug
22
4
740
8
.34.
Shimomura
M
, Toyota
K
, Karakuchi
N
, Ono
K
, Tsukiyama
N
, Shishida
M
. Prognostic nutritional index predicts treatment outcomes following palliative surgery for colorectal adenocarcinoma
. J Anus Rectum Colon
. 2017
;1
(4
):118
–24
.35.
Taniai
T
, Haruki
K
, Hamura
R
, Fujiwara
Y
, Furukawa
K
, Gocho
T
. The prognostic significance of C-reactive protein-to-lymphocyte ratio in colorectal liver metastases
. J Surg Res
. 2021 Feb
258
414
21
.36.
Taylor
AE
, Nicolson
VM
, Cunningham
D
. Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment
. Br J Cancer
. 1995 Jan
71
1
92
6
.37.
Goere
D
, Daveau
C
, Elias
D
, Boige
V
, Tomasic
G
, Bonnet
S
. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma
. Eur J Surg Oncol
. 2008 Dec
34
12
1335
9
.38.
Lee
SJ
, Lee
J
, Lim
HY
, Kang
WK
, Choi
CH
, Lee
JW
. Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis
. Cancer Chemother Pharmacol
. 2010 Jul
66
2
229
35
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
